Phase II Study of Thalidomide in Combination With Capecitabine in Patients With Metastatic Breast Cancer
Upon determination of eligibility, patients will be receive:
Thalidomide + Capecitebine
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall response rate
18 Months
No
Howard Burris, MD
Principal Investigator
Sarah Cannon Research Institute
United States: Institutional Review Board
SCRI BRE 60
NCT00193102
April 2001
June 2010
Name | Location |
---|